Dr. Debra Yu has been appointed vice president of strategy, WuXi PharmaTech. Dr. Yu will be responsible for leading the company's strategic planning and initiatives. She will report to Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.
Prior to joining the company, Dr. Yu co-led Pfizer's venture capital group and was instrumental in working in areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a general partner at Delphi Ventures and a managing director at Bay City Capital, two Bay area venture firms focused on the life sciences. Dr. Yu has also held senior positions at many leading companies and organizations like McKinsey & Co., the FDA, the Wilkerson Group, Morgan Stanley & Co., Genentech and the Permanente Co.
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li. "With 19 years of experience in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."